Drugs.com - Clinical Trials

Vividion Therapeutics Doses First Patient in Phase I Study of RAS-PI3Kα Inhibitor VVD-159642 for Treatment of Advanced Solid Tumors

San Diego, CA, USA, Berlin, Germany, April 3, 2025 – Vividion Therapeutics, Inc. (Vividion) today announced that the first patient has been dosed in a Phase I clinical trial evaluating VVD-159642, an investigational oral inhibitor designed to...

Apr 8, 2025 - 03:58
 0
Vividion Therapeutics Doses First Patient in Phase I Study of RAS-PI3Kα Inhibitor VVD-159642 for Treatment of Advanced Solid Tumors
San Diego, CA, USA, Berlin, Germany, April 3, 2025 – Vividion Therapeutics, Inc. (Vividion) today announced that the first patient has been dosed in a Phase I clinical trial evaluating VVD-159642, an investigational oral inhibitor designed to...
Read More

Tags:

Previous Article

Rilzabrutinib Granted Orphan Drug Designation in the US for Two Rare Diseases wi...

Next Article

Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track D...

Related Posts

Eledon Pharmaceuticals Announces Use of Tegoprubart as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a Human

Eledon Pharmaceuticals Announces Use of Tegoprubart as ...

Feb 9, 2025  0

FDA Grants Orphan Drug Designation for Bexmarilimab in MDS

FDA Grants Orphan Drug Designation for Bexmarilimab in MDS

Mar 5, 2025  0

Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease

Biogen’s Investigational Tau-Targeting Therapy BIIB080 ...

Apr 8, 2025  0